10-Q: Biogen Reports Q2 2026 Results Amidst Apellis Integration

Biogen Inc. announced its Q2 2026 financial results, highlighting revenue growth driven by rare disease and specialized immunology products, alongside increased R&D and SG&A expenses due to strategic acquisitions and product launches.

Summary

• Biogen Inc. reported total revenue of $2.74 billion for the three months ended June 30, 2026, a 3.4% increase from the prior year, driven by growth in rare disease and specialized immunology products.
• Product revenue, net, increased by 2.0% to $1.92 billion, with notable growth in Rare Disease products (up 10.8%) and the inclusion of Specialized Immunology products (SYFOVRE and EMPAVELI) contributing $127.8 million.
• Multiple Sclerosis (MS) revenue saw a decline of 13.0% to $963.3 million, primarily due to generic competition for TECFIDERA and a long-term trend of patients switching from Interferon therapies.
• Research and development (R&D) expenses increased by 32.7% to $529.6 million, influenced by higher amortization of acquired inventory, increased clinical trial spending, and operating expenses from the Apellis acquisition.
• Selling, general, and administrative (SG&A) expenses rose by 21.6% to $709.7 million, largely due to the integration of Apellis and increased sales and marketing efforts for new product launches.
• Net income attributable to Biogen Inc. decreased significantly to $97.5 million ($0.66 per diluted share) from $634.8 million ($4.33 per diluted share) in the prior year, impacted by higher costs and expenses.
• The company completed the acquisition of Apellis Pharmaceuticals, Inc. on May 14, 2026, for approximately $5.3 billion, adding SYFOVRE and EMPAVELI to its portfolio.
• Biogen also entered into a definitive agreement to acquire RayThera Inc. in June 2026, further expanding its pipeline in immunology.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant drop in net income and EPS, despite revenue growth, driven by increased costs and competitive pressures in key product areas.

Positives

• Total revenue increased by 3.4% to $2.74 billion for the quarter.
• Rare Disease product revenue grew by 10.8% to $601.7 million.
• Specialized Immunology products (SYFOVRE and EMPAVELI) contributed $127.8 million in revenue following the Apellis acquisition.
• Alzheimer's collaboration revenue from LEQEMBI increased by 16.0% to $63.7 million.
• Net cash flow from operating activities increased significantly to $1.1 billion for the six months ended June 30, 2026, compared to $420.2 million in the prior year.
• The FDA approved the supplemental BLA for LEQEMBI subcutaneous autoinjector in July 2026.
• Breakthrough Therapy designation was granted for litifilimab for CLE in January 2026 and for salanersen for SMA in June 2026.
• The company expects continued growth in rare disease revenue and U.S. ZURZUVAE revenue.

Negatives

• Net income attributable to Biogen Inc. decreased by 84.8% to $97.5 million for the quarter.
• Diluted earnings per share decreased by 84.8% to $0.66.
• Multiple Sclerosis (MS) revenue declined by 13.0% to $963.3 million due to generic competition for TECFIDERA and patient shifts away from Interferon therapies.
• TECFIDERA revenue specifically dropped by 53.0% to $90.9 million due to multiple generic entrants.
• Cost of sales increased by 28.4% to $776.9 million, driven by higher amortization of acquired inventory step-up adjustments.
• Acquired in-process R&D, upfront and milestone expense increased significantly by 251.9% to $164.0 million, largely due to upfront payments for new collaborations.
• Cash, cash equivalents, and marketable securities decreased by 69.7% to $1.3 billion, primarily due to the Apellis acquisition funding.
• The company anticipates higher net interest expense going forward.

Risks

• Substantial dependence on revenue from a limited number of products, facing increasing competition from generics and biosimilars.
• Potential for adverse legal, administrative, geopolitical, regulatory, or legislative developments impacting product pricing and reimbursement.
• Challenges in commercializing new products like LEQEMBI and SKYCLARYS due to reimbursement, commercial strategy, and reputation risks.
• High uncertainty and cost associated with the development of new products and additional indications for existing products.
• Failure to compete effectively due to new, more efficacious, safer, or less expensive alternatives from competitors.
• Potential for adverse safety events or required restrictions on product use, which could negatively impact business, sales, and stock price.
• Cybersecurity threats and data breaches could lead to liability, operational disruption, and reputational damage.
• Manufacturing issues, reliance on third parties, and compliance with stringent regulatory requirements pose risks to supply and costs.

Future Outlook

Biogen expects continued growth in rare disease revenue and U.S. ZURZUVAE revenue. However, the company anticipates a decline in total MS revenue due to competition and expects higher net interest expense. The company believes its existing funds, combined with cash generated from operations and access to additional financing, are sufficient for future needs.

Management Comments

• The addition of Apellis is expected to enhance Biogen's short- and long-term revenue growth profile by adding two commercialized, differentiated, specialized immunology products.
• Biogen expects total MS revenue to decline in 2026 due to high levels of competition.
• Biogen expects TECFIDERA revenue to be adversely impacted by accelerating generic competition.
• Biogen expects TYSABRI revenue to continue to be adversely affected by the entrance of a biosimilar.
• Biogen expects selling, general and administrative expense for 2026 to increase when compared to 2025, due to integration efforts and product launch investments.

Industry Context

StockSavvy.ai notes that Biogen's Q2 2026 results reflect the ongoing challenges in the Multiple Sclerosis market due to generic and biosimilar competition, a trend impacting many established biopharmaceutical companies. The company's strategic acquisitions and pipeline investments in specialized immunology and rare diseases are key to its future growth, aligning with industry trends of portfolio diversification and focus on high-unmet-need areas.

Legal Proceedings

• Securities litigation related to ADUHELM, LEQEMBI, TECFIDERA, and VUMERITY is ongoing, with one action preliminarily approved for settlement.
• Derivative actions related to ADUHELM and LEQEMBI are stayed.
• IMRALDI patent litigation is ongoing in Germany, with a decision pending.
• Humana filed suit against Biogen regarding patient assistance programs.
• Genentech litigation resulted in a judgment against Biogen for approximately $124.3 million, with an appeal pending.
• Antitrust litigation has been filed concerning contracts with pharmacy benefit managers for TECFIDERA and VUMERITY.
• TECFIDERA EU litigation involves multiple generic companies counterclaiming damages.
• TYSABRI biosimilar patent litigation is ongoing, with a trial scheduled for April 2027.

Stakeholder Impact

• Shareholders may be impacted by the significant decrease in net income and EPS, despite revenue growth.
• Patients may benefit from new therapies like SYFOVRE and EMPAVELI, but face continued competition impacting established MS treatments.
• Employees may be affected by integration activities following the Apellis acquisition and ongoing restructuring efforts.

Next Steps

• Continue integration of Apellis operations.
• Explore next steps for the BIIB091 asset in relapsing-remitting multiple sclerosis.
• Advance litifilimab to registrational development.
• Continue to monitor and manage the impact of generic and biosimilar competition.
• Pursue potential acquisition of RayThera Inc. in Q3 2026.

Key Dates

Recommendation

While Biogen shows revenue growth and strategic acquisitions in promising areas like specialized immunology and rare diseases, the significant decline in profitability due to increased costs and intense competition in its core MS business warrants a cautious approach. The ongoing legal proceedings and integration challenges also present risks. A 'hold' recommendation reflects the balance between potential future growth drivers and current operational headwinds.

Keywords

Biogen, 10-Q, Quarterly Report, Pharmaceuticals, Biotechnology, Neurology, Immunology, Rare Diseases